World Malaria Day 2026
Malaria is preventable and treatable, yet claimed 610,000 lives in 2024 - over 75% of which were children. With modern science and effective funding, this tragic statistic is avoidable.
Despite significant progress over two decades, recent figures reveal a troubling plateau. With an estimated 282 million cases in 2024, malaria remains a persistent barrier to prosperity, hitting Sub-Saharan Africa hardest, where 95% of the global burden falls.
World Malaria Day’s 2026 theme - 'Driven to End Malaria: Now We Can. Now We Must'- calls for global action and reminds us that, for the first time in history, we possess the scientific capability to eliminate this ancient disease. Yet, while our science is advancing at an unprecedented rate, financial and political commitment is faltering. A growing funding gap risks dismantling progress and threatens driving a resurgence of malaria.
UK-led research has been pivotal in advancing the fight against malaria. British scientist Sir Ronald Ross first discovered that mosquitoes transmit the malaria parasite in 1897. The Innovative Vector Control Consortium (IVCC), backed by UK funding, developed next-generation insecticide-treated bed nets. These showed dramatically higher efficiency than previous versions, particularly in high-resistance areas.
The UK has also led significant developments in malaria vaccines, most notably the R21/Matrix-M vaccine - a major achievement for British science. With over 75% efficacy and a manufacturing cost of just $2.99 per dose, it represents the most cost-effective weapon in the history of the fight. Through funding provided to Gavi, the Vaccine Alliance, the UK has supported the vaccine rollout of these lifesaving tools. As of 2026, Gavi has delivered over 50 million doses across Africa, with a target to fully immunise an additional 50 million children by 2030. This investment has helped enable a strategic shift from defence (insecticide-treated bed nets) to offence (immunisation).
The World Malaria Report warns of mounting ‘biological challenges’: confirmed drug and insecticide resistance, diagnostic failures, and expanding populations of invasive, insecticide-resistant mosquitoes. The climate crisis and the impact of conflict pose equally damning threats to the elimination of malaria. Compounded with systemic global aid cuts and funding well below target, these emerging threats risk undoing years of progress.
Amongst those cutting funding in the fight against malaria is the UK. The Government pledged £850 million to the Global Fund to Fight AIDS, Tuberculosis and Malaria's latest replenishment - a 15% cut from 2022 funding and the lowest since 2010. Similarly, the Gavi commitment significantly dropped to £1.25 billion from £1.65 billion. Combined with USAID cuts, this funding retreat comes at a critical time.
The funding gap is not only a humanitarian failure, it’s a fundamental strategic risk for the UK. Malaria destabilises development, collapsing health systems and creating grounds for economic instability and regional insecurity. The argument for funding international development is rooted in security: in an interconnected world, prosperity depends on the resilience of our global partnerships. Strengthening these ties reinforces Britain's role as a force for good on the global stage.
Investment in malaria control delivers substantial, measurable returns beyond disease elimination: stronger health systems, more resilient economies, and a robust defence against future pandemics. The fight against malaria is a win for everyone, creating a safer, more prosperous world. British science has long contributed to developments in this field; we cannot finish the job on a reduced budget.
